Table 23.15 Cancer of the Prostate (Invasive)

Estimated United States Cancer Prevalence Counts on January 1, 2017 By Race/Ethnicity and Years Since Diagnosis

| Years Since Diagnosis | 0 to 5 | > 5 to 10 | > 10 to 15 | > 15 to 20 | > 20 to 25 | <=25 ^b | > 25 ^d | Complete ^e |
|------------------------|---------|-----------|------------|------------|------------|-------------------|-------------------|-----------------------|
| Race All Races | 900,214 | 953,463 | 678,436 | 418,862 | 184,721 | 3,135,696 | 34,643 | 3,170,339 |
| White | 701,239 | 769,223 | 563,050 | 354,061 | 159,744 | 2,547,317 | 36,576 | 2,583,893 |
| Black | 138,010 | 131,943 | 86,907 | 50,644 | 20,399 | 427,902 | 4,086 | 431,988 |
| Asian/Pacific Islander | 21,319 | 20,629 | 13,351 | 6,827 | 2,333 | 64,458 | + | + |
| Hispanic | 59,273 | 57,004 | 38,768 | 20,529 | 7,678 | 183,252 | + | + |

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years By Age at Prevalence and Race/Ethnicity

| | Age Specific (Crude) | | | | | | | Age-Adjusted ^c | | | |
|--------------------------|----------------------|--------|--------|--------|--------|--------|--------|---------------------------|---------|---------|----------|
| Age at Prevalence | All Ages | 0-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60-69 | 70-79 | 80+ | All Ages |
| <u>Race</u> All Races | 1.9646 | 0.0001 | 0.0002 | 0.0003 | 0.0007 | 0.0628 | 0.9938 | 4.9473 | 12.7506 | 17.7721 | 1.8324 |
| White | 2.0311 | 0.0002 | 0.0003 | 0.0003 | 0.0005 | 0.0480 | 0.8646 | 4.5811 | 12.2431 | 17.3251 | 1.7432 |
| Black | 1.9574 | - | _ | 0.0002 | 0.0017 | 0.1674 | 1.9500 | 8.2063 | 18.4635 | 22.7226 | 2.7051 |
| Asian/Pacific Islander | 0.6447 | - | - | - | - | 0.0144 | 0.2968 | 1.9438 | 5.7590 | 9.4841 | 0.8397 |
| Hispanic | 0.6240 | 0.0002 | 0.0002 | 0.0001 | 0.0005 | 0.0286 | 0.5448 | 3.1347 | 9.2044 | 13.7068 | 1.3137 |

US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census. а

b

Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Complete prevalence is obtained by summing <=25 and > 25.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Not available.